Grifols (GIKLY) Assets (2010 - 2025)
Grifols (GIKLY) reported Assets of $22.9 billion for Q4 2025, little changed on a YoY basis from $22.9 billion in Q4 2024, and little changed quarter-over-quarter from $22.9 billion in Q4 2024.
Grifols (GIKLY) Assets (2010 - 2025) Analysis & Trends
Grifols has reported Assets for 16 years, with the latest figure at $22.9 billion in Q4 2025.
- For the quarter ending Q4 2025, Assets changed 0.32% year-over-year to $22.9 billion; the trailing twelve-month figure through Dec 2025 stood at $22.9 billion (changed 0.32% YoY), and the FY2025 full-year result was $22.9 billion, up 28227.93% from the prior year.
- Assets for Q4 2025 stood at $22.9 billion, roughly flat from $22.9 billion in the prior quarter.
- The five-year high for Assets was $22.9 billion in Q4 2025, with the low at $21.7 billion in Q4 2022.
- Historically, Assets has averaged $22.4 billion across 5 years, with a median of $22.6 billion in 2023.
- Annual changes were most pronounced in 2021 — Assets increased 20.82% — and 2022, when it slipped 1.56%.
- Grifols' Assets stood at $22.0 billion in 2021, then fell by 1.56% to $21.7 billion in 2022, then increased by 4.28% to $22.6 billion in 2023, then advanced by 1.27% to $22.9 billion in 2024, then advanced by 0.32% to $22.9 billion in 2025.
- The last three Assets figures came in at $22.9 billion (Q4 2025), $22.9 billion (Q4 2024), and $22.6 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 84.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Grifols | - | - | - | 22.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.95 Bn |
| Dec 31, 2024 | 22.87 Bn |
| Dec 31, 2023 | 22.59 Bn |
| Dec 31, 2022 | 21.66 Bn |
| Dec 31, 2021 | 22.00 Bn |
| Dec 31, 2020 | 18.21 Bn |
| Sep 30, 2020 | 18.28 Bn |
| Mar 31, 2020 | 17.55 Bn |
| Dec 31, 2019 | 17.20 Bn |
| Sep 30, 2019 | 15.62 Bn |
| Mar 31, 2019 | 15.22 Bn |
| Dec 31, 2018 | 14.24 Bn |
| Sep 30, 2018 | 13.70 Bn |
| Jun 30, 2018 | 13.65 Bn |
| Mar 31, 2018 | 16.45 Bn |
| Dec 31, 2017 | 12.86 Bn |
| Jun 30, 2017 | 12.22 Bn |
| Dec 31, 2016 | 10.94 Bn |
| Sep 30, 2016 | 10.68 Bn |
| Jun 30, 2016 | 10.78 Bn |